» Articles » PMID: 7799030

Cytokine Levels and Systemic Toxicity in Patients Undergoing Isolated Limb Perfusion with High-dose Tumor Necrosis Factor, Interferon Gamma, and Melphalan

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1995 Jan 1
PMID 7799030
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF), interferon gamma, and melphalan (M) has been reported to result in high response rates for extremity melanoma and sarcoma. We have evaluated the relationship of systemic TNF exposure to induction of several secondary mediators and incidence of systemic toxicity.

Patients And Methods: Nineteen patients with extremity melanoma (n = 16) or sarcoma (n = 3), underwent 90-minute ILP with TNF-alpha, interferon gamma (0.2 mg), and M (10 to 13 mg/L of limb volume) (TNF/IFN/M) (n = 12), or M alone (n = 7). Continuous intraoperative monitoring (CIM) for systemic leak from the perfusion circuit was performed using radioactive iodine-131 albumin. Cytokine levels in the perfusate and systemic circulation during and after ILP were measured by enzyme-linked immunosorbent assay.

Results: Systemic leaks > or = 1% from the perfusion circuit occurred in six patients who received TNF/IFN/M and in four who received M alone. Hypotension that required vasopressor support occurred in six of six patients with evidence of a leak (> or = 1%) and zero of six patients without a leak (< 1%). These six patients had significantly higher peak systemic TNF levels during and after perfusion than patients without a leak (2.8 and 8.2 ng/mL v 0.7 and 2.0 ng/mL, respectively; P < .05). All patients who received TNF/IFN/M had significantly greater increases in systemic interleukin-6 (IL-6) levels than in patients with M alone (12,395 +/- 10,374 pg/mL v 79.4 +/- 7.2 pg/mL, respectively; P < .001). Intracellular adhesion molecule (ICAM), IL-8, and TNF-R levels were also increased after ILP with TNF/IFN/M.

Conclusion: ILP with TNF/IFN/M can be safely performed, as I131 albumin provides a sensitive measure of systemic leakage from the perfusion circuit. Patients with a measured leak of > or = 1% develop mild and transient postoperative hypotension with significantly higher systemic TNF levels and lower perfusate TNF levels than in patients without leaks.

Citing Articles

Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins.

Grogg J, Vernet R, Charrier E, Urwyler M, von Rohr O, Saingier V iScience. 2023; 26(8):107372.

PMID: 37539029 PMC: 10393802. DOI: 10.1016/j.isci.2023.107372.


Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli P, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J Sci Transl Med. 2014; 6(261):261ra151.

PMID: 25378643 PMC: 4373413. DOI: 10.1126/scitranslmed.3010162.


Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.

Herman J, Wild A, Wang H, Tran P, Chang K, Taylor G J Clin Oncol. 2013; 31(7):886-94.

PMID: 23341531 PMC: 4820756. DOI: 10.1200/JCO.2012.44.7516.


Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.

Alexander Jr H, Fraker D, Bartlett D, Libutti S, Steinberg S, Soriano P J Clin Oncol. 2009; 28(1):114-8.

PMID: 19901107 PMC: 2799229. DOI: 10.1200/JCO.2009.23.7511.


Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.

Dodds M, Frederiksen K, Skak K, Hansen L, Lundsgaard D, Thompson J Cancer Immunol Immunother. 2008; 58(6):843-54.

PMID: 18925392 PMC: 11030868. DOI: 10.1007/s00262-008-0600-8.